• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD
Versartis, Inc. - Product Pipeline Review - 2012 Product Image

Versartis, Inc. - Product Pipeline Review - 2012

  • ID: 2194003
  • July 2012
  • 39 pages
  • Global Markets Direct

Versartis, Inc. – Product Pipeline Review – 2012

Summary

Global Market Direct’s pharmaceuticals report, “Versartis, Inc. - Product Pipeline Review - 2012” provides data on the Versartis, Inc.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Versartis, Inc.’s corporate website, SEC filings, investor presentations and featured press releases, both from Versartis, Inc. and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- Versartis, Inc. - Brief Versartis, Inc. overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Versartis, Inc. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment READ MORE >

2
List of Tables 4
List of Figures 4
Versartis, Inc. Snapshot 5
Versartis, Inc. Overview 5
Key Information 5
Key Facts 5
Versartis, Inc. – Research and Development Overview 6
Key Therapeutic Areas 6
Versartis, Inc. – Pipeline Review 8
Pipeline Products by Stage of Development 8
Pipeline Products – Monotherapy 9
Pipeline Products – Combination Treatment Modalities 10
Versartis, Inc. – Pipeline Products Glance 11
Versartis, Inc. Clinical Stage Pipeline Products 11
Phase I Products/Combination Treatment Modalities 11
Versartis, Inc. – Early Stage Pipeline Products 12
Pre-Clinical Products/Combination Treatment Modalities 12
Discovery Products/Combination Treatment Modalities 13
Versartis, Inc. – Drug Profiles 14
VRS-317 14
Product Description 14
Mechanism of Action 14
R&D Progress 14
VRS-808 16
Product Description 16
Mechanism of Action 16
R&D Progress 16
VRS-826 17
Product Description 17
Mechanism of Action 17
R&D Progress 17
VRS-859 + AMX-808 18
Product Description 18
Mechanism of Action 18
R&D Progress 18
Versartis, Inc. – Pipeline Analysis 20
Versartis, Inc. – Pipeline Products by Therapeutic Class 20
Versartis, Inc. – Pipeline Products By Target 21
Versartis, Inc. – Pipeline Products by Route of Administration 22
Versartis, Inc. – Pipeline Products By Mechanism of Action 23
Versartis, Inc. – Recent Pipeline Updates 24
Versartis, Inc. – Locations And Subsidiaries 25
Head Office 25
Versartis, Inc., Recent Developments 26
Versartis, Inc.- Press Release 26
Jun 25, 2012: Versartis Presents Positive Results From Phase I Study Of VRS-317 At ENDO 2012 26
Jun 07, 2012: Versartis Announces Publication Of Preclinical Data Of VRS-317 In Journal Of Pharmaceutical Sciences 27
Nov 15, 2009: XTEN Data From Amunix And Versartis Featured In Nature Biotechnology As A Novel Platform For Increasing Serum Half-life Of Protein Therapeutics 28
Sep 23, 2009: Versartis Presents Preclinical Data For VRS-317 29
Sep 14, 2009: Versartis To Provide Update On Product VRS-317 (HGH-XTEN) At Two Technology Conferences 29
Jun 10, 2009: Versartis Presents Positive Preclinical Data On Two Product Candidates 30
Jun 10, 2009: Versartis Presents Positive Preclinical Data On VRS-317 At Endo 09 30
Jun 10, 2009: Versartis Presents Positive Preclinical Data On VRS-826 31
Jun 10, 2009: Versartis Presents Positive Preclinical Data On VRS-826 At Endo 09 31
Jun 05, 2009: Versartis Publishes Preclinical Abstracts For VRS-808 At 2009 American Diabetes Association Scientific Sessions 31
Financial Deals Landscape 33
Versartis, Inc., Deals Summary 33
Versartis, Inc., Pharmaceuticals & Healthcare, Deal Details 34
Venture Financing 34
Versartis Secures $21 Million In Series B Financing Round 34
Versartis Secures $11 Million In Series A Financing 36
Licensing Agreements 37
Diartis Pharma Enters Into Licensing Agreement With Versartis For VRS-859 37
Appendix 38
Methodology 38
Coverage 38
Secondary Research 38
Primary Research 38
Expert Panel Validation 38
Contact Us 39
Disclaimer 39

List of Tables
Versartis, Inc., Key Information 5
Versartis, Inc., Key Facts 5
Versartis, Inc. – Pipeline by Indication, 2012 7
Versartis, Inc. – Pipeline by Stage of Development, 2012 8
Versartis, Inc. – Monotherapy Products in Pipeline, 2012 9
Versartis, Inc. – Combination Treatment Modalities in Pipeline, 2012 10
Versartis, Inc. – Phase I, 2012 11
Versartis, Inc. – Pre-Clinical, 2012 12
Versartis, Inc. – Discovery, 2012 13
Versartis, Inc. – Pipeline By Therapeutic Class, 2012 20
Versartis, Inc. - Pipeline By Target, 2012 21
Versartis, Inc. – Pipeline By Route of Administration, 2012 22
Versartis, Inc. – Pipeline Products By Mechanism of Action, 2012 23
Versartis, Inc. – Recent Pipeline Updates, 2012 24
Versartis, Inc., Deals Summary 33
Versartis Secures $21 Million In Series B Financing Round 34
Versartis Secures $11 Million In Series A Financing 36
Diartis Pharma Enters Into Licensing Agreement With Versartis For VRS-859 37

List of Figures
Versartis, Inc. – Pipeline by Indication, 2012 7
Versartis, Inc. – Pipeline by Stage of Development, 2012 8
Versartis, Inc. – Monotherapy Products in Pipeline, 2012 9
Versartis, Inc. – Combination Treatment Modalities in Pipeline, 2012 10
Versartis, Inc. – Pipeline By Therapeutic Class, 2012 20
Versartis, Inc. - Pipeline By Target, 2012 21
Versartis, Inc. – Pipeline By Route of Administration, 2012 22
Versartis, Inc. - Pipeline Products By Mechanism of Action, 2012 23

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos